Josee
Farmer, Health Care Policy Intern
The
convoluted and complex process of vaccine development – which includes an
exploratory stage, pre-clinical stage, three phases of clinical trials,
regulatory review and licensing, as well as large-scale manufacturing – can
take anywhere from 8 to 18 years, usually falling within the 10 to 15 year
range. Amid the COVID-19 pandemic, the race to develop a vaccine on a much
shorter timeline has become a central goal of drug manufacturers and health
experts. While several COVID-19 treatment drugs are already in phase 2 and
phase 3 clinical trials, Moderna’s mRNA-1273 is currently the vaccine furthest
in the development process. This vaccine entered phase 1 of clinical testing on
March 16th, in which testing on 45 healthy adults began, and phase 2 is
expected to begin in a few months, with a significantly larger testing pool.
Moderna projects the vaccine will likely become available in 12 to 18 months
but may be available for emergency use by the public in Fall 2020. The vaccine
mRNA-1273 took roughly two months to arrive at phase 1 of clinical testing,
while the typical vaccine development takes 3 to 6 years to arrive at this
point.
COVID-19 mRNA-1273 data obtained from Moderna and
other vaccine development data obtained from the Centers for Disease Control
and Prevention link to History of
Vaccines, AbbVie, NCBI, and Sanofi
FROM TEAM HEALTH
Daily Dish: Recent Trends in Insulin Prices – AAF
President Douglas Holtz-Eakin
Rising insulin prices certainly affect diabetics, but the effects are felt more broadly, too.
Rising insulin prices certainly affect diabetics, but the effects are felt more broadly, too.
Taking the Voters’ Pulse on Pharmaceuticals – Douglas
Holtz-Eakin
AAF’s recent polling on voters’ attitudes toward various drug-pricing policy proposals provides a valuable guide to an issue that will doubtless re-emerge in the future.
AAF’s recent polling on voters’ attitudes toward various drug-pricing policy proposals provides a valuable guide to an issue that will doubtless re-emerge in the future.
Daily Dish: A Look Back at Pressing Health Policy Issues – Douglas
Holtz-Eakin
Voters’ preferred approach to reforming drug pricing is re-designing Medicare Part D to make it more affordable and put downward pressure on prices.
Voters’ preferred approach to reforming drug pricing is re-designing Medicare Part D to make it more affordable and put downward pressure on prices.
WORTH A LOOK
Kaiser Health News: Newsom’s Ambitious Health Care Agenda
Crumbles In A ‘Radically Changed’ World
Health Affairs: Integrating Health And Human Services In
California’s Whole Person Care Medicaid 1115 Waiver Demonstration
https://www.americanactionforum.org/weekly-checkup/the-global-drug-supply-chain/#ixzz6JWFtGWKL
Follow @AAF on Twitter
Follow @AAF on Twitter
No comments:
Post a Comment